Bubs Australia Achieves Key Milestone with 400th Infant Enrolled in Clinical Trial

Bubs Australia Limited (ASX: BUB) has successfully enrolled its 400th infant in the Growth Monitoring Study (GMS), a crucial step towards gaining permanent market access in the U.S. infant formula market. The trial, which began in August 2023, is part of the regulatory process set by the U.S. FDA. It evaluates Bubs' Goat Milk and two Cow Milk formulas, along with a control and a breastfeeding cohort. Under the guidance of Dr. Keith Aqua, the trial aims to transition Bubs from 'temporary enforcement discretion' to full FDA approval by October 2025. This milestone signifies Bubs' progress in the regulatory process and its commitment to providing high-quality nutrition to American families.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com